A retrospective analysis of locally advanced EGFR-mutated NSCLC patients with durvalumab after chemoradiotherapy

被引：0
|
作者：
Uchida, Yoshiyasu [1 ]
Ninomiya, Takashi [1 ]
Harada, Daijiro [1 ]
Kozuki, Toshiyuki [1 ]
机构：
[1] Natl Hosp Org Shikoku Canc Ctr, Dept Thorac Oncol & Med, Matsuyama, Ehime, Japan
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.05.126
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO11-4
引用
收藏
页码：S488 / S488
页数：1
相关论文
共 50 条
  • [21] Osimertinib in Resected EGFR-Mutated NSCLC
    Tsuboi, Masahiro
    Herbst, Roy S.
    Wu, Yi-Long
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (14): : 1341 - 1342
  • [22] Osimertinib with Chemotherapy in EGFR-Mutated NSCLC
    van Doorn-Khosrovani, Sahar Barjesteh van Waalwijk
    Badrising, Sushil K.
    Burgers, Sjaak
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (05): : 478 - 479
  • [23] Gefitinib Approved for EGFR-Mutated NSCLC
    不详
    CANCER DISCOVERY, 2015, 5 (09) : 896 - 896
  • [24] Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis
    Yi, Lilan
    Fan, Junsheng
    Qian, Ruolan
    Luo, Peng
    Zhang, Jian
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (01) : 284 - 294
  • [25] Simulation in the Management of EGFR-Mutated Advanced NSCLC: Seeing Beyond Age
    Carey, Christine
    Herrmann, Tara
    Warters, Martin
    Blevins, Douglas
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S270 - S270
  • [26] Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
    Cho, Byoung C.
    Lu, Shun
    Felip, Enriqueta
    Spira, Alexander I.
    Girard, Nicolas
    Lee, Jong-Seok
    Lee, Se-Hoon
    Ostapenko, Yurii
    Danchaivijitr, Pongwut
    Liu, Baogang
    Alip, Adlinda
    Korbenfeld, Ernesto
    Mourao Dias, Josiane
    Besse, Benjamin
    Lee, Ki-Hyeong
    Xiong, Hailin
    How, Soon-Hin
    Cheng, Ying
    Chang, Gee-Chen
    Yoshioka, Hiroshige
    Yang, James C. -H.
    Thomas, Michael
    Nguyen, Danny
    Ou, Sai-Hong I.
    Mukhedkar, Sanjay
    Prabhash, Kumar
    D'Arcangelo, Manolo
    Alatorre-Alexander, Jorge
    Vazquez Limon, Juan C.
    Alves, Sara
    Stroyakovskiy, Daniil
    Peregudova, Marina
    Sendur, Mehmet A. N.
    Yazici, Ozan
    Califano, Raffaele
    Gutierrez Calderon, Vanesa
    de Marinis, Filippo
    Passaro, Antonio
    Kim, Sang-We
    Gadgeel, Shirish M.
    Xie, John
    Sun, Tao
    Martinez, Melissa
    Ennis, Mariah
    Fennema, Elizabeth
    Daksh, Mahesh
    Millington, Dawn
    Leconte, Isabelle
    Iwasawa, Ryota
    Lorenzini, Patricia
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (16): : 1486 - 1498
  • [27] Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
    Rosenfeld, Roberto
    NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (06): : 619 - 620
  • [28] Predictors of Health Utility Scores (HUS) in Advanced EGFR-Mutated NSCLC
    Jiang, S.
    Hurry, M.
    Hueniken, K.
    Brown, M. C.
    Liang, M.
    Patel, D.
    Labbe, C.
    Eng, L.
    Naik, H.
    Bradbury, P.
    Leighl, N.
    Shepherd, F.
    Xu, W.
    Liu, G.
    Walton, R.
    O'Kane, G.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S420 - S421
  • [29] Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases
    Zhang, Jinyao
    Wang, Yan
    Liu, Ziling
    Wang, Lin
    Yao, Yu
    Liu, Yutao
    Hao, Xue Zhi
    Wang, Jianyang
    Xing, Puyuan
    Li, Junling
    THORACIC CANCER, 2021, 12 (24) : 3407 - 3415
  • [30] Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy
    Aredo, J. V.
    Hellyer, J. A.
    Neal, J. W.
    Padda, S. K.
    McCoach, C. E.
    Riess, J. W.
    Cabebe, E. C.
    Loo, B. W.
    Diehn, M.
    Wakelee, H. A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S15 - S15
12345